Show simple item record

dc.contributor.authorEdmonds, Kim
dc.contributor.authorSpencer-Shaw, Andrea
dc.date.accessioned2010-08-09T13:15:20Z
dc.date.available2010-08-09T13:15:20Z
dc.date.issued2010-08-09T13:15:20Z
dc.identifier.citationManaging adverse events associated with sorafenib in renal cell carcinoma., 19 (1):58-60 Br J Nursen
dc.identifier.issn0966-0461
dc.identifier.pmid20081715
dc.identifier.urihttp://hdl.handle.net/10541/109292
dc.description.abstractSorafenib, a multi-targeted kinase inhibitor, is approved in Europe for the treatment of patients with advanced renal cell carcinoma whose treatment with an interferon or interleukin-2-based therapy has previously failed, or who are unsuitable for such therapy. Unlike some first-generation anti-cancer therapies, sorafenib is generally associated with moderate and manageable adverse events. Some of the most common adverse events include a hand-foot skin reaction, diarrhoea and rash. As nurses provide an interface between the patient and the clinical team, it is important that they understand how sorafenib-related adverse events impact on patients. It is equally vital that nurses are able to recognize and manage these adverse events. Our experience has shown that with patient education, early reporting, monitoring and treatment, the adverse events of sorafenib therapy can be easily and effectively managed. Optimal adverse event management helps ensure treatment compliance and ensures that patients receive maximum benefit from therapy.
dc.language.isoenen
dc.subjectDiarrhoeaen
dc.subjectKidney Canceren
dc.subject.meshAlopecia
dc.subject.meshAntineoplastic Agents
dc.subject.meshBenzenesulfonates
dc.subject.meshCarcinoma, Renal Cell
dc.subject.meshDiarrhea
dc.subject.meshDrug Eruptions
dc.subject.meshFatigue
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshKidney Neoplasms
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPatient Education as Topic
dc.subject.meshProtein Kinase Inhibitors
dc.subject.meshPyridines
dc.titleManaging adverse events associated with sorafenib in renal cell carcinoma.en
dc.typeArticleen
dc.contributor.departmentThe Royal Marsden Hospital, London.en
dc.identifier.journalBritish Journal of Nursingen
html.description.abstractSorafenib, a multi-targeted kinase inhibitor, is approved in Europe for the treatment of patients with advanced renal cell carcinoma whose treatment with an interferon or interleukin-2-based therapy has previously failed, or who are unsuitable for such therapy. Unlike some first-generation anti-cancer therapies, sorafenib is generally associated with moderate and manageable adverse events. Some of the most common adverse events include a hand-foot skin reaction, diarrhoea and rash. As nurses provide an interface between the patient and the clinical team, it is important that they understand how sorafenib-related adverse events impact on patients. It is equally vital that nurses are able to recognize and manage these adverse events. Our experience has shown that with patient education, early reporting, monitoring and treatment, the adverse events of sorafenib therapy can be easily and effectively managed. Optimal adverse event management helps ensure treatment compliance and ensures that patients receive maximum benefit from therapy.


This item appears in the following Collection(s)

Show simple item record